Characterization and transplantation of induced megakaryocytes from hematopoietic stem cells for rapid platelet recovery by a two-step serum-free procedure

Experimental Hematology

Volumn 37, Issue 11, 2009, Pages

  Chen, Te Wei ^a,b   Hwang, Shiaw Min ^a   Chu, I Ming ^b   Hsu, Shu Ching ^c   Hsieh, Tzu Bou ^a   Yao, Chao Ling ^a,d  

^a FOOD INDUSTRY RESEARCH AND DEVELOPMENT INSTITUTE   (Taiwan)

^b NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d YUAN ZE UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CD41A ANTIGEN; CD61 ANTIGEN; CYTOKINE; LYMPHOCYTE ANTIGEN; MEMBRANE ANTIGEN; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR NF E2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CELL ACTIVATION; CELL THERAPY; CONTROLLED STUDY; CULTURE MEDIUM; EX VIVO STUDY; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MEGAKARYOCYTE; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SCID MOUSE; STEM CELL EXPANSION; THROMBOCYTE COUNT;

MUS;

ANIMALS; ANTIGENS, CD34; BLOOD CELLS; BLOOD PLATELETS; BONE MARROW CELLS; CELL CULTURE TECHNIQUES; CULTURE MEDIA; CULTURE MEDIA, SERUM-FREE; CYTOKINES; FETAL BLOOD; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELLS; HUMANS; INTEGRIN BETA3; MEGAKARYOCYTES; MICE; MICE, INBRED NOD; MICE, SCID; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; RADIATION CHIMERA; THROMBOPOIESIS;

EID: 70349835131     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2009.07.012     Document Type: Article

References (32)

1. Giannini E.G. Thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther 23 (2006) 1055-1065
2. Wagner J.E., Rosenthal J., Sweetman R., et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood 88 (1996) 795-802
3. Kanamaru S., Kawano Y., Watanabe T., et al. Low numbers of megakaryocyte progenitors in grafts of cord blood cells may result in delayed platelet recovery after cord blood cell transplant. Stem Cells 18 (2000) 190-195
4. Webb I.J., and Anderson K.C. Risks, costs, and alternatives to platelet transfusions. Leuk Lymphoma 34 (1999) 71-84
5. Tijssen M.R., van der Schoot C.E., Voermans C., and Zwaginga J.J. Clinical approaches involving thrombopoietin to shorten the period of thrombocytopenia after high-dose chemotherapy. Transfus Med Rev 20 (2006) 283-293
6. Matsunaga T., Tanaka I., Kobune M., et al. Ex vivo large-scale generation of human platelets from cord blood CD34+ cells. Stem Cells 24 (2006) 2877-2887
7. Scheding S., Bergmannn M., Rathke G., Vogel W., Brugger W., and Kanz L. Additional transplantation of ex vivo generated megakaryocytic cells after high-dose chemotherapy. Haematologica 89 (2004) 630-631
8. Yao C.L., Liu C.H., Chu I.M., Hsieh T.B., and Hwang S.M. Factorial designs combined with the steepest ascent method to optimize serum-free media for ex vivo expansion of human hematopoietic progenitor cells. Enzyme Microb Technol 33 (2003) 343-352
9. Yao C.L., Feng Y.H., Lin X.Z., Chu I.M., Hsieh T.B., and Hwang S.M. Characterization of serum-free ex vivo-expanded hematopoietic stem cells derived from human umbilical cord blood CD133+ cells. Stem Cells Dev 15 (2006) 70-78
10. Kao I.T., Yao C.L., Kong Z.L., Wu M.L., Chuang T.L., and Hwang S.M. Generation of natural killer cells from serum-free, expanded human umbilical cord blood CD34+ cells. Stem Cells Dev 16 (2007) 1043-1051
11. Chen T.W., Yao C.L., Chu I.M., Chuang T.L., Hsieh T.B., and Hwang S.M. Large generation of megakaryocytes from serum-free expanded human CD34(+) cells. Biochem Biophys Res Commun 378 (2009) 112-117
12. Woo S.Y., Kie J.H., Ryu K.H., et al. Megakaryothrombopoiesis during ex vivo expansion of human cord blood CD34+ cells using thrombopoietin. Scand J Immunol 55 (2002) 88-95
13. Miyazaki R., Ogata H., Iguchi T., et al. Comparative analyses of megakaryocytes derived from cord blood and bone marrow. Br J Haematol 108 (2000) 602-609
14. Mattia G., Vulcano F., Milazzo L., et al. Different ploidy levels of megakaryocytes generated from peripheral or cord blood CD34+ cells are correlated with different levels of platelet release. Blood 99 (2002) 888-897
15. van Hensbergen Y., Schipper L.F., Brand A., et al. Ex vivo culture of human CD34+ cord blood cells with thrombopoietin (TPO) accelerates platelet engraftment in a NOD/SCID mouse model. Exp Hematol 34 (2006) 943-950
16. Ignatz M., Sola-Visner M., Rimsza L.M., et al. Umbilical cord blood produces small megakaryocytes after transplantation. Biol Blood Marrow Transplant 13 (2007) 145-150
17. Han Z.C., Bellucci S., and Caen J.P. Megakaryocytopoiesis: characterization and regulation in normal and pathologic states. Int J Hematol 54 (1991) 3-14
18. Sonoda Y., Kuzuyama Y., Tanaka S., et al. Human interleukin-4 inhibits proliferation of megakaryocyte progenitor cells in culture. Blood 81 (1993) 624-630
19. Berthier R., Valiron O., Schweitzer A., and Marguerie G. Serum-free medium allows the optimal growth of human megakaryocyte progenitors compared with human plasma supplemented cultures: role of TGF beta. Stem Cells 11 (1993) 120-129
20. Catani L., Amabile M., Luatti S., et al. Interleukin-4 downregulates nuclear factor-erythroid 2 (NF-E2) expression in primary megakaryocytes and in megakaryoblastic cell lines. Stem Cells 19 (2001) 339-347
21. Kostyak J.C., and Naik U.P. Megakaryopoiesis: transcriptional insights into megakaryocyte maturation. Front Biosci 12 (2007) 2050-2062
22. Shivdasani R.A., Rosenblatt M.F., Zucker-Franklin D., et al. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell 81 (1995) 695-704
23. Mattia G., Milazzo L., Vulcano F., et al. Long-term platelet production assessed in NOD/SCID mice injected with cord blood CD34+ cells, thrombopoietin-amplified in clinical grade serum-free culture. Exp Hematol 36 (2008) 244-252
24. Perez L.E., Rinder H.M., Wang C., Tracey J.B., Maun N., and Krause D.S. Xenotransplantation of immunodeficient mice with mobilized human blood CD34+ cells provides an in vivo model for human megakaryocytopoiesis and platelet production. Blood 97 (2001) 1635-1643
25. Ramirez M., Regidor C., Marugan I., Garcia-Conde J., Bueren J.A., and Fernandez M.N. Engraftment kinetics of human CD34+ cells from cord blood and mobilized peripheral blood co-transplanted into NOD/SCID mice. Bone Marrow Transplant 35 (2005) 271-275
26. Angelopoulou M., Novelli E., Grove J.E., et al. Cotransplantation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice. Exp Hematol 31 (2003) 413-420
27. Tijssen M.R., van Hennik P.B., di Summa F., Zwaginga J.J., van der Schoot C.E., and Voermans C. Transplantation of human peripheral blood CD34-positive cells in combination with ex vivo generated megakaryocytes results in fast platelet formation in NOD/SCID mice. Leukemia 22 (2008) 203-208
28. Bruno S., Gunetti M., Gammaitoni L., et al. Fast but durable megakaryocyte repopulation and platelet production in NOD/SCID mice transplanted with ex-vivo expanded human cord blood CD34+ cells. Stem Cells 22 (2004) 135-143
29. Bruno S., Gunetti M., Gammaitoni L., et al. In vitro and in vivo megakaryocyte differentiation of fresh and ex-vivo expanded cord blood cells: rapid and transient megakaryocyte reconstitution. Haematologica 88 (2003) 379-387
30. Ratajczak M.Z., Ratajczak J., Machalinski B., Mick R., and Gewirtz A.M. In vitro and in vivo evidence that ex vivo cytokine priming of donor marrow cells may ameliorate posttransplant thrombocytopenia. Blood 91 (1998) 353-359
31. Cortin V., Garnier A., Pineault N., Lemieux R., Boyer L., and Proulx C. Efficient in vitro megakaryocyte maturation using cytokine cocktails optimized by statistical experimental design. Exp Hematol 33 (2005) 1182-1191
32. Bertolini F., Battaglia M., Pedrazzoli P., et al. Megakaryocytic progenitors can be generated ex vivo and safely administered to autologous peripheral blood progenitor cell transplant recipients. Blood 89 (1997) 2679-2688